Rothenberg et al. 1 sought to demonstrate the noninferiority of XELOX to FOLFOX-4 as second-line therapy in patients with progressive disease during or shortly after first-line therapy with ...
XELOX: Capecitabine and oxaliplatin. The Common Terminology Criteria for Adverse Events can be found at [201] and the WHO criteria can be found at [202]. 5-FU: 5-fluorouracil; ADR: Adverse drug ...
Recent advances in surgical and loco-regional treatment of CLM require precise diagnostic imaging techniques for optimal patient selection. First of all, more accurate imaging is essential to ...
Akeso, Inc. (9926.HK) today announced that the positive interim analysis results from Phase III clinical study of Cadonilimab (PD-1/CTLA-4 BsAb) combined with XELOX (capecitabine plus oxaliplatin) as ...
Akeso, Inc. (9926.HK) today announced that the positive interim analysis results from Phase III clinical study of Cadonilimab (PD-1/CTLA-4 BsAb) combined with XELOX (capecitabine plus oxaliplatin) as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback